



Corporate Presentation

October 25, 2019

CEL-SCI Corporation

Geert Kersten
Chief Executive Officer

8229 Boone Boulevard, Suite 802
Vienna, VA 22182, USA
-
Phone: **(703) 506-9460**

NYSE American: **CVM**

Forward Looking Statements

This presentations contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. You can generally identify these forward-looking statements by forward-looking words such as “anticipates,” “believes,” “expects,” “intends,” “future,” “could,” “estimates,” “plans,” “would,” “should,” “potential,” “continues” and similar words or expressions (as well as other words or expressions referencing future events, conditions or circumstances). These forward-looking statements involve risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements, including, but not limited to: the progress and timing of, and the amount of expenses associated with, our research, development and commercialization activities for our product candidates, including Multikine; the success of our clinical studies for our product candidates; our ability to obtain U.S. and foreign regulatory approval for our product candidates and the ability of our product candidates to meet existing or future regulatory standards; our expectations regarding federal, state and foreign regulatory requirements; the therapeutic benefits and effectiveness of our product candidates; the

safety profile and related adverse events of our product candidates; our ability to manufacture sufficient amounts of Multikine or our other product candidates for use in our clinical studies or, if approved, for commercialization activities following such regulatory approvals; our plans with respect to collaborations and licenses related to the development, manufacture or sale of our product candidates; our expectations as to future financial performance, expense levels and liquidity sources; our ability to compete with other companies that are or may be developing or selling products that are competitive with our product candidates; anticipated trends and challenges in our potential markets; and our ability to attract, retain and motivate key personnel.

All forward-looking statements contained herein are expressly qualified in their entirety by this cautionary statement, the risk factors set forth under the heading “Risk Factors” and elsewhere in our public filings, and in the documents incorporated or deemed to be incorporated by reference therein. The forward-looking statement contained in this presentation speak only as of their respective dates. Except to the extent required by applicable laws and regulations, we undertake no obligation to update these forward-looking statements to reflect new information, events or circumstances after the date of this presentation. In light of these risks

and uncertainties, the forward-looking events and circumstances described in this presentation may not occur and actual results could differ materially from those anticipated or implied in such forward-looking statements. Accordingly, you are cautioned not to place undue reliance on these forward-looking statements.

FDA Disclaimer Statement

Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized in this presentation involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled Phase 3 clinical trial of this investigational therapy that is currently in progress. Each page of this presentation must be looked at in the context of the whole presentation, not by itself, and is merely meant to be a summary of the full and detailed information on the Company in its public filings and its website.

Potential conclusions could only be drawn if the initial observations in the early-phase studies relating to the potential adverse events associated with Multikine administration in treating head and neck cancer are confirmed in the well controlled Multikine Phase 3 clinical study, CEL-SCI's Phase 3 study is completed successfully, and the FDA licenses the product following their review of all of the data related to Multikine submitted in CEL-SCI's license application.

Working to Create the First Cancer Drug to Be Administered Before Surgery


Multikine is administered to previously untreated, newly diagnosed head and neck cancer patients right after diagnosis for three weeks before the current standard of care treatments (surgery followed by radiation or combined radio-chemotherapy). There is no delay of surgery or follow on standard of care treatments. The intent of adding Multikine treatment to the current standard of care treatment regimen is to either cure the patient or increase the time to recurrence of the patient's cancer since there is a known correlation between increased time to recurrence and increased survival of patients. No severe toxicity was reported as being associated with Multikine when it was added to the current standard of care in phase II clinical trials. Our experience in our Phase 3 study with respect to toxicity has paralleled what was seen during the Phase 2 studies.

The most common misconception with respect to the use of Multikine is that it is in competition with all of the FDA approved immunotherapies (e.g., Keytruda, Opdivo, CAR-T, and many more) that have been recently in the news. In contrast to Multikine these other immunotherapies are indicated only for patients whose cancers have recurred following standard of care treatment (surgery etc.) or those patients with metastatic cancer where surgery is no longer an option. The use of these other cancer immunotherapies in the patient population being treated with Multikine would be inappropriate and unethical because they are administered over many months, which would cause a delay in the application of the currently used standard of care treatment which is potentially curative on its own. Further, the extreme toxicities that may be associated with these new products would preclude their use in patients that are potentially curable by the current standard of care.

We are at the end of an eight year Phase III clinical trial to prove this novel way of treating cancer.

Phase 3 Study Design -Timing of Multikine Treatment Regimen

Advanced Primary Head and Neck Cancer



Introducing The Management Team



Geert R. Kersten
Director and CEO






- CEO since 1995; joined in 1987
- 30+ years pioneering field of cancer immunotherapy
- Previously worked at the law firm of Finley & Kumble and Source Capital, an investment bank
- Undergraduate degree Accounting, MBA from George Washington and JD from American University



Eyal Talor, Ph.D.
Chief Scientific Officer

- CSO since 2009; joined in 1993
- 23+ years of managing clinical R&D development for immunotherapy application
- Served as Director of Clinical Laboratories; and as R&D Director at CBL
- Author of over 30 publications
- Ph.D. at University of Ottawa and Post Doc at Johns Hopkins

Introducing The Management Team

Officer Title		Joined CVM	Years of Exp.	Background
	Patricia B. Prichep SVP of Operations	1992	40+	<ul style="list-style-type: none">• Former Manager of Quality and Productivity for the NASD• BA from the University of Bridgeport
	Daniel Zimmerman, Ph.D. SVP of Cellular Immunology	1996	40+	<ul style="list-style-type: none">• Author of over 40 scientific publications and dozen patents• Former Senior Staff Fellow at NIH• PhD and Masters U. of Florida; BS Emory and Henry College
	John Cipriano SVP of Regulatory Affairs	2004	48+	<ul style="list-style-type: none">• Former FDA Deputy Director of Biologics IND Division• BS Massachusetts College of Pharmacy and MS (Medicinal Chemist) Purdue University
	William Jones VP of Quality Assurance	1999	30+	<ul style="list-style-type: none">• QA positions at Novartis in US and Europe• Former GMP compliance officer at NCI's Frederick facility• BS from George Mason and MS from Hood College
	Todd Burkhart VP of Manufacturing	2010	30+	<ul style="list-style-type: none">• Previously involved in the building and/or running a number of major pharmaceutical facilities at Cephalon, HGS, and Univax• BS from Tusculum College

Product Candidates

Candidate	Preclinical	Phase 1	Phase 2	Phase 3	Marketing approval
-----------	-------------	---------	---------	---------	--------------------

MULTIKINE

Head and neck cancer

Neoadjuvant therapy in patients with squamous cell carcinoma of the head and neck (administered right after diagnosis, before the first standard cancer treatment) – Global Pivotal Phase 3 Study

HPV

Cervical dysplasia in HIV/HPV co-infected patients (University of Maryland)

L.E.A.P.S. Technology

Rheumatoid Arthritis CEL-2000:

Phase 1 enabling Studies CEL-4000 (NIH Grant)

Pandemic Flu treatment:

(NIAID)

Breast Cancer

Boosting the Immune System Before the Ravages of Radiation/Chemotherapy

- Give immune system drugs while the immune system is still strong, before surgery, radiation and chemotherapy
- Increase success rate of first cancer treatment by adding our immune stimulating product candidate Multikine to the current standard of care (SOC) for advanced primary (not yet treated) head and neck cancer
- Help the immune system “see” the tumor
- World’s largest Phase 3 trial in advanced primary head and neck cancer
 - 928 patients are enrolled. Full enrollment was completed in September 2016. We are currently waiting for 298 events (deaths) in the two main groups to prove an overall survival benefit.
- There is one recommended standard of care for advanced primary head and neck cancer. Chance to establish a new first line standard of care.
- Checkpoint inhibitors, CAR T-cell therapy, etc. cannot be used in this patient population. They are used only in recurrent / metastatic head and neck cancer patients.

What is Multikine?

- Multikine is an investigational patented mass produced biological product manufactured following Good Manufacturing Practice (GMP) requirements from "Source Leukocytes" – an FDA licensed product - at CEL-SCI's manufacturing facility near Baltimore, MD
- Cytokine Cancer Immunotherapy, contains 14 natural human cytokines, the body's regulators of the immune system
- This pro-inflammatory cytokine mixture includes interleukins, interferons, chemokines and colony-stimulating factors - elements of the body's natural mix of defenses against cancer
- Research at the US National Institute of Health has shown that the cytokines in Multikine (shown in **red** in the table) are the ones that are required to reject any tumor

Major Cytokine(s) and other Cellular Products in Multikine

IL-1 α	IL-6
IL-1β	IL-8
IL-2	TNF-β
IL-3	G-CSF
TNF-α	RANTES
IFN-γ	MIP-1α
GM-CSF	MIP-1β

11 Clinical Studies Have Been Completed Across Indications for Multikine


Phase	Indication	No. of subjects	Countries	Published paper
Phase 1/2	Head & Neck Cancer Recurrent	16	U.S. & Canada	N/A
Pilot Study	Head & Neck Cancer Recurrent	4	U.S.	Arch Otolaryngol Head and Neck Surgery
Phase 1/2	Head & Neck Cancer Pre-surgery	12	Israel	Arch Otolaryngol Head and Neck Surgery
Phase 2	Head & Neck Cancer Pre-surgery	28	Canada	N/A
Phase 2	Head & Neck Cancer Pre-surgery	31	Hungary	Laryngoscope, ASCO Annual Meeting
Phase 2	Head & Neck Cancer Pre-surgery	21	Hungary	ASCO, Journal of Clinical Oncology and Oral Oncology
Phase 2	Head & Neck Cancer Pre-surgery	30	Poland & Czech Republic	N/A
Pilot Study	Prostate Cancer Pre-Surgery Treatment	5	U.S.	Seminars in Oncology
Pilot Studies	Different cancer tumors	54	U.K. & others	Lymphokine
Phase 1	Cervical Dysplasia in HPV Induced Cervical Cancer	8	U.S.	Annals of the 33 rd International Congress of the Society of Gynecological Oncologists
Phase 1/2	HIV	15	U.S.	Antiviral Therapy
Total Patients		224		

Why Head and Neck Cancer as a First Target?

- Advanced (stages 3 and 4) primary (not yet treated) head and neck cancer was selected as the first indication because:
 - Represents an unmet medical need
 - Last FDA approval of a therapy for advanced primary head and neck cancer was about 60 years ago
 - Awarded Orphan Drug Status in the US
 - Head and neck cancer represents a very large cancer
 - Only one standard of care throughout the world
- Multikine administration is well suited as an addition to the established SOC in H&N cancer
 - SOC is surgery followed by either radiation or concurrent radiation/chemotherapy
 - During the 3-4 week preparation & scheduling of surgery, the Multikine investigational treatment regime is administered for 3 weeks, 5 times per week, with no impact on scheduling of and administration of SOC treatment
- Once successful we plan to develop Multikine for the treatment of other cancers


Head and Neck Cancer Market

- World-wide about **650,000** new head and neck cancer patients diagnosed per year



- Advanced primary head and neck cancer constitutes about 2/3 of all head and neck cancer patients
- Neoadjuvant treatment. Use right after diagnosis, before surgery.
- Improvement in overall survival should result in Multikine becoming part of a new standard of care: Multikine followed by (plus) the 'old' SOC

Mechanism of Action Stimulates an Immune Response at the Injection Site



Multikine Showed Measurable Anti-Tumor Responses in 3 Weeks Only

The final “Proof of Concept” Phase 2 study, following multiple Phase 2 studies that tested different treatment regimens, selected the best treatment for patients. The treatment regimen in this final Phase 2 study is the same as used in the Phase 3 study

Of the evaluable patients - **10.5%** of patients had no remaining cancer cells (by pathology) following 3 weeks of Multikine alone

Timar et al: Journal of Clinical Oncology 23 (15) May 20, 2005
and Talor et al, Oral Oncology Supplement (2) No. 1, May 2007

The remaining treated patients in the study had about a **50%** average reduction in the number of cancer cells (by pathology) following 3 weeks of Multikine alone

Timar et al: Journal of Clinical Oncology 23 (15) May 20, 2005

42.1% Overall Response Rate (RECIST) in Phase 2 study

Timar et al: Journal of Clinical Oncology 23 (15) May 20, 2005

Quality of life observations:

(as reported by clinical study investigators)

Reduction in pain. Patients are able to open their mouths more easily.
Patients with tongue cancer can move their tongues again within a few days.
Many patients gain weight.

Multikine Increased Overall Survival (OS) by 33%

Approximately three years after the same “Proof of Concept” Phase 2 study we obtained the patients’ and their families’ consents for a survival follow-up

Survival results in this Final “Proof of Concept” Phase 2 study were compared to results from 55 clinical trials in the same patient population (Advanced Primary SCCHN) treated with SOC only


Follow-up Endpoint	Standard of Care (SOC)* +/- All other Treatment Modalities	Multikine** + Standard of Care	% Improvement over SOC***
Overall Survival (at 3.3 years from treatment)	47.5%	63.2%	33.1%

* Survey of 55 clinical trials; advanced primary H&N cancer (published 1987 – 2007)
** Multikine Treatment: Phase 2 Clinical Trial (Timar et al, JCO, 23(15): May 2005)
*** Talor et al, Oral Oncology Supplement (2) No. 1, May 2007 Literature survey of 55 clinical trials; advanced primary H&N cancer (published 1987 – 2007)

Pathology: Non-Treated – vs. – Multikine Treated (Final Phase 2 study)


Oral Squamous Cell Carcinoma (Locally Advanced Primary H&N Cancer)

Histological appearance of necrosis in Oral Squamous Cell Carcinoma (OSCC) [HE staining]:



Non-Multikine treated

Lack of necrosis in the epithelial nests of OSCC



Multikine treated

Entire cancer nest is necrotic and filled with debris and leukocytes

Phase 3 Trial Partners

National Institutes of Health, USA

—
genetic and molecular markers from tumor samples derived from Phase 3 study patients

Teva Pharmaceutical Industries Ltd., Israel (NYSE:TEVA)

—
licensee for several countries

Orient Europharma Co. Ltd., Taiwan

—
licensee for several Far Eastern countries

Ergomed PLC, UK

—
CRO that completed Phase 3 patient enrollment, contributed up to \$12 million towards the cost of the Phase 3 study

About 100 top medical research institutes, universities and hospitals around the world participating in the Phase 3 study

Multikine Exhibits a Consistent Safety Profile Across Phase 1 and 2 Studies

- Multikine is administered in supra-physiological doses locally (near or close) to the tumor and the adjacent lymph nodes. The known cytokines contained in Multikine are present in amounts well below any published levels that would impart toxicity.
- Phase 1 and Phase 2 clinical trials with Multikine: Most commonly reported Adverse Events associated with the administration of the investigational therapy Multikine were:
 - Pain at the injection site
 - Local minor bleeding at the injection site
 - Edema at the injection site
 - Diarrhea
 - Headache
 - Nausea
 - Constipation

(as reported by the Phase 1 and 2 clinical investigators)

NOTE: No SAE directly associated with Multikine was reported

- Phase 2 Study by Feinmesser et al published on a series of 12 patients with advanced primary SCCHN* treated with Multikine Investigational product candidate concluded that: “No significant toxic effect of the treatment was registered in any of the patients participating in the study during or after treatment.” (Arch Otolaryngol H&N Surg. (Vol 129), AUG 2003)

* SCCHN = Squamous Cell Carcinoma Head & Neck

How Does the Multikine Treatment Patient Population Differ from the Checkpoint Inhibitor Patient Population?

The checkpoint inhibitor Keytruda® by Merck was approved for head and neck cancer in June 2019, but it was approved for a very different patient population than that which CEL-SCI is pursuing.

Keytruda was approved for patients with head and neck squamous cell carcinoma that has spread (metastatic) or recurred after the initial cancer treatments and cannot be removed by surgery, and where the tumor tests positive for PD-L1.

CEL-SCI is pursuing the advanced primary patients who have just been diagnosed with advanced primary squamous cell carcinoma of the head and neck and are scheduled for “intent to cure” treatment with surgery plus radiation or chemoradiation.

State-of-the-Art Facility & Proprietary Manufacturing Process: Potential Barriers to Competition

- cGMP and BSL-1 facility
 - Built specifically for Multikine – but could easily be Multi-use
 - State-of-the art facility
 - Over 73,000 ft² of Manufacturing and R&D space available
 - About 35,000 ft² fully developed – room for growth
 - Scaled for commercial use
- We spent over 10 years and approx. \$80 million developing and validating the Multikine manufacturing process
- Significant investment has been made (~\$25 million) in the Multikine manufacturing plant
- Construction began in August 2007 and Plant and Process validation completed in 2010
- Inspected several times by European Qualified Person (QP)
 - Inspected by the QP for the manufacture and release of Sterile Medicinal Products (per ICH and EU Directives)
- Significant “know how” developed to manufacture Multikine – Method of Manufacture
 - Trade-secret

Intellectual Property Protection for Multikine

Patents and other protection for Multikine:

- Composition of matter patent protection until 2024
 - US Patent # 6,896,879
 - European Patent (Germany) # 1,773,395
 - European Patents: #1,753,452; #1,773,368; #1,879,618
 - Chinese Patent # ZL200480025403.6
 - Japanese Patent # 5,122,279
- Additional pending patent applications world-wide
- US FDA granted Orphan drug designation for the “neoadjuvant therapy in patients with squamous cell carcinoma of the head and neck”
 - Gives potential for 7 year market exclusivity upon approval

Proprietary quality control and manufacturing know-how

- This is most important since Multikine is a complex biologic and very hard to copy

When Will the Phase 3 Study End?

- The study started in early 2011 and the last patient was enrolled in September 2016.
 - All cancer patients have been in the study for 3 to 8.5 years.
- Patients are currently being followed for overall survival and other protocol specified endpoints. Two hundred ninety eight (298) events (deaths) (Event-Drive study) must occur among the 2 main comparator groups (almost 800 patients out of the 928 patients enrolled) to be able to assess if the primary endpoint of this pivotal Phase 3 study has been met
 - A 10% improvement in overall survival in patients treated with Multikine treatment regimen plus Standard of Care (SOC) vs. patients treated with SOC alone
- The study protocol assumes an overall survival rate of about 55% at 3 years for the SOC treatment group alone, but obviously patients continue to die from cancer and other causes beyond 3 years. The next slide will show that in fact there has been no improvement in the Standard of Care treatments. Survival of the specific groups selected for this Phase 3 trial is actually worse than what we had assumed for the study
- "In contrast to declines for the most common cancers, death rates rose from 2012 through 2016 for ... sites within the oral cavity and pharynx ..." (American Cancer Society, January 8, 2019)

Estimated Overall Survival (OS) using the SOC for the Study Population Enrolled in CEL-SCI's Phase 3 Clinical Trial

- Three (3) Year OS – Approximately 47%
- Five (5) Year OS – Approximately 37%

Year	OS Estimate	95% Confidence Bound
1	71.42%	(69.84%, 72.92%)
2	53.86%	(52.09%, 55.59%)
3	46.59%	(44.74%, 48.42%)
4	41.98%	(40.02%, 43.93%)
5	36.75%	(34.475%, 39.03%)

The SEER Data was queried and data extracted by an external Statistical Group.

What is SEER data? SEER is an authoritative source for cancer statistics in the United States. The Surveillance, Epidemiology, and End Results (SEER) Program provides information on cancer statistics in an effort to reduce the cancer burden among the U.S. population. SEER is supported by the Surveillance Research Program (SRP) in NCI's Division of Cancer Control and Population Sciences (DCCPS).

- In CEL-SCI's Phase 3 study, approximately 135 patients were enrolled in the study from 2011 to 2013, approximately 195 were enrolled in 2014, approximately 340 in 2015, and approximately 260 in 2016

Who Has the Unblinded Data from the Phase 3 Study?

- CEL-SCI is blinded to the study results
- Only the regulators, the Independent Data Monitoring Committee (IDMC) and select members of the CRO have unblinded information
- The FDA and 23 other regulators have reviewed detailed annual reports from the Phase 3 study for the last eight years and never had any questions
- The Phase 3 study and its data have been repeatedly reviewed by the IDMC, who have reviewed safety results and efficacy indicators and recommended that the trial continue until 298 events have occurred, as recently as October 2019

Why is the Multikine Study an Event Driven Study?

- By now it is well established that cancer immunotherapy has a “delayed survival” benefit. In a time driven study you end the study at a certain time point (e.g., two years after the last drug was administered). Under this scenario, the study may be ended before the survival benefit has materialized.
- To avoid this problem the Multikine study waits for a certain number of events to occur. The advantage is that hopefully the survival benefit of Multikine can be captured. The “disadvantage” is that a successful Multikine will delay the end of the study since a successful Multikine is designed to cure cancer patients or delay their time to cancer recurrence.

Can the study not end early if things look good?

- Looking good is not “good enough” in an event driven study. You need an adequate level of statistical power (at least 80%) to prove that the drug works. If you end the study short of the required 298 events, you may lack the required statistical power to prove the efficacy of the Multikine.

Key Developments Pointing to Likelihood of Success of Phase 3 Study

- To prove a 10% improvement in overall survival, the study requires CEL-SCI to wait until 298 events have occurred among the two main groups. In Phase 2 studies, Multikine increased survival by 33%.
- We believe a delay in reaching these 298 deaths could be a good sign for the success of the study.
- In October 2019, the IDMC recommended to "*continue the trial until the appropriate number of events has occurred.*" Since the study has been going on for 8.5 years, the last patients were enrolled over three years ago and is finally very near to its end, they should have a fairly clear idea whether it can be successful or not. If it could not be successful, they could have called it "futile" as other IDMCs did for Biogen, Abbvie, Mallinckrodt and Clovis during 2019.
- In conjunction with outside experts we have reviewed in detail any other factors we could think of that allow these cancer patients to live much longer than expected. None of the other factors appear to be able to produce this good result. Therefore, we believe that Multikine should be responsible for the patients living longer.


The next slide was presented by Dr. Chen, Executive Director of Global Biometrics Sciences with Bristol-Myers Squibb, at the EMA-CDDF Joint Meeting, London, UK in February 2016. It discusses the final clinical trial for Yervoy (Ipililumab), the first cancer immunotherapy blockbuster drug. This trial also used the Event Driven design that is being used in the CEL-SCI Phase 3 study.

Lessons Learned

(Event-Driven vs. Time-Driven Design)

- Ipilimumab in front-line metastatic melanoma
 - Estimated study duration: 3 years
- 3 years after study start
 - ~85% of anticipated number of events
 - Decreasing event rate
 - ~84% statistical power
- Study continued for another 1.5~2 years for the remaining 15% of number of events
- Un-blinding occurred with a couple events short of design

CEL-SCI Stock Chart and Key Events - August 1, 2018 through October 25, 2019



Top 5 Institutional Investors



Shares Out	34,066,914
Top 5 Holders:	4,421,871
Top 5 % of S/O:	12.98%

as of June 30, 2019

Rank	Investor Name	Current Position	% S/O	Quarterly Change	Position Date
1	BlackRock (Combined)	1,813,654	5.32%	1,272,955	6/30/2019
2	The Vanguard Group, Inc.	1,332,334	3.91%	346,999	6/30/2019
3	D.A. Davidson & Co.	517,600	1.52%	117,900	6/30/2019
4	State Street Global Advisors (US)	434,324	1.27%	398,099	6/30/2019
5	Geode Capital Management, L.L.C.	323,959	0.95%	202,636	6/30/2019

Total Institutional Ownership	6,097,000	17.90%
-------------------------------	-----------	--------

Late Stage Cancer Company Acquisitions in the Past 2 Years

Company	Ticker	Sales price	Phase, Indication(s) and Acquisition
Kite Pharma Bought by Gilead	KITE	\$11.9 B	<ul style="list-style-type: none"> Phase 1&2/3 Solid Tumors, ALL,NHL, Multiple Myeloma, CLL, AML Acquired by Gilead for \$11.9 B (August 2017)
Juno Therapeutics Bought by Celgene	JUNO	\$9.8 B	<ul style="list-style-type: none"> Phase 1 & 2 NHL, ALL, Multiple Myeloma, NSCLC, Mesothelioma, Ovarian, Breast, Lung, Neuroblastoma Acquired by Celgene for \$9 B net of 9.7% already owned (January 2018)
Impact Biomedicines Bought by Celgene	Private	\$7 B	<ul style="list-style-type: none"> Phase 3 myelofibrosis and polycythemia vera Acquired by Celgene for up to \$7 B (January 2018)
TESARO Bought by GlaxoSmithKline	TSRO	\$5.1 B	<ul style="list-style-type: none"> Acquired by GlaxoSmithKline for \$5.1 B (December 2018)
Loxo Oncology Bought by Eli Lilly	LOXO	\$8 B	<ul style="list-style-type: none"> FDA approved first commercial medicine in 2018 Acquired by Eli Lilly for \$8 B (January 2019)

LEAPS: A Separate Technology

CEL-SCI's LEAPS technology is a platform technology for therapeutic vaccines

- A patented new class of drug with a novel approach, acting earlier in the pathway of the specific disease
- Efficacy demonstrated in six human diseases by animal challenge models; three autoimmune (two different arthritis models representing Th1 and Th17 conditions, and myocarditis), two infectious (Herpes Simplex Virus and influenza A), and oncology (breast cancer)
- Research has been funded via collaborations with the NIH, U.S. Army, Navy, Universities and has received National Institutes of Health grants (e.g., SBIR)
- Primary focus: development of a therapeutic vaccine for Rheumatoid Arthritis (RA)
- Sept 2017: CEL-SCI was awarded a \$1.5 million SBIR grant from NIH to fund GMP manufacturing, IND enabling studies, and additional mechanism of action studies to advance its first LEAPS product candidate for RA towards an IND application

Summary

- Multikine is administered before surgery, radiation and chemotherapy because that is the time when the patient's immune system is the strongest. By doing so we hope to either cure the patient or delay the time to recurrence
- Phase 3 overall survival (OS) data results are expected soon
- Endpoint of 10% improvement in OS over comparator arm in Phase 3 study. In our completed Phase 2 we saw a 33.1% improvement over the average OS for the current SOC (from scientific literature) at 3.3 years post-surgery
- No severe toxicity associated with Multikine in Phase 2 studies and in the Phase 3 study
- Head and neck cancer is a major cancer with ~650,000 new cases p.a. worldwide
- Other cancer immunotherapies, e.g., Keytruda, Opdivo, CAR-T, etc., cannot be used before surgery since they require long periods for administration and a delay in surgery is not permitted
- No new FDA approved treatments for advanced primary head and neck cancer in about 60 years (unmet medical need) Multikine granted Orphan Drug designation in U.S.

Closing

The Multikine Phase 3 trial is the largest head and neck cancer study ever. Head and neck cancer is one of the biggest cancers worldwide with about 650,000 new patients per year. CEL-SCI's Phase 3 study enrolled the last of its 928 patients about three years ago and the final data read out is expected soon. If successful, we believe Multikine has the potential to become the first recommended treatment for patients following diagnosis of head and neck cancer. Advanced primary head and neck cancer represents an unmet medical need because the last FDA approval for this disease was about 60 years ago. The FDA has also granted Orphan Drug designation to Multikine. First line treatments in general command a premium to the market because the market is so much larger than that for a recurrent cancer treatment.

To repeat, other immunotherapies such as Keytruda, Opdivo, CAR-T, etc. are indicated only for patients whose cancers have recurred following standard of care (surgery etc.) therapy or those patients with metastatic cancer where surgery is no longer an option. The use of these other cancer immunotherapies in the patient population being treated with Multikine would be inappropriate and unethical because they are administered over many months, which would cause a delay in the application of the currently used standard of care treatment which is potentially curative on its own. Further, the extreme toxicities that may be associated with these new products would preclude their use in patients that are potentially curable by the current standard of care.



CEL-SCI Corporation

Geert Kersten
Chief Executive Officer

8229 Boone Boulevard, Suite 802
Vienna, VA 22182, USA

-

Phone: **(703) 506-9460**

NYSE American: **CVM**